JP2018505169A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018505169A5 JP2018505169A5 JP2017539594A JP2017539594A JP2018505169A5 JP 2018505169 A5 JP2018505169 A5 JP 2018505169A5 JP 2017539594 A JP2017539594 A JP 2017539594A JP 2017539594 A JP2017539594 A JP 2017539594A JP 2018505169 A5 JP2018505169 A5 JP 2018505169A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- optionally substituted
- compound
- hydrogen
- heterocyclyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CCC1CC*(Cc2ccccc2)CC1 Chemical compound CCC1CC*(Cc2ccccc2)CC1 0.000 description 11
- WATASAJREKAPOT-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1OC)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1OC)=O WATASAJREKAPOT-UHFFFAOYSA-N 0.000 description 1
- FFROMNOQCNVNIH-UHFFFAOYSA-N CC(C)CC1CCCCC1 Chemical compound CC(C)CC1CCCCC1 FFROMNOQCNVNIH-UHFFFAOYSA-N 0.000 description 1
- PIAWUDAHTYGVCH-UHFFFAOYSA-N COC(c1ccc(CN2CCC(CNC(C3)C33c4ccccc4CCC3)CC2)cc1)=O Chemical compound COC(c1ccc(CN2CCC(CNC(C3)C33c4ccccc4CCC3)CC2)cc1)=O PIAWUDAHTYGVCH-UHFFFAOYSA-N 0.000 description 1
- MQLFSPBSNWUXSO-UHFFFAOYSA-N ICC1CCOCC1 Chemical compound ICC1CCOCC1 MQLFSPBSNWUXSO-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562110209P | 2015-01-30 | 2015-01-30 | |
| US62/110,209 | 2015-01-30 | ||
| PCT/US2016/015440 WO2016123387A1 (en) | 2015-01-30 | 2016-01-28 | Therapeutic compounds and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018505169A JP2018505169A (ja) | 2018-02-22 |
| JP2018505169A5 true JP2018505169A5 (enExample) | 2019-03-07 |
| JP6636031B2 JP6636031B2 (ja) | 2020-01-29 |
Family
ID=55361970
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017539594A Expired - Fee Related JP6636031B2 (ja) | 2015-01-30 | 2016-01-28 | 治療用化合物およびその使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US10301253B2 (enExample) |
| EP (1) | EP3250552B1 (enExample) |
| JP (1) | JP6636031B2 (enExample) |
| CN (1) | CN107438593B (enExample) |
| WO (1) | WO2016123387A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106045862B (zh) * | 2015-04-10 | 2019-04-23 | 上海迪诺医药科技有限公司 | 环丙胺类螺(杂)环化合物、其药物组合物及应用 |
| US10059668B2 (en) | 2015-11-05 | 2018-08-28 | Mirati Therapeutics, Inc. | LSD1 inhibitors |
| KR102720551B1 (ko) | 2015-12-29 | 2024-10-21 | 미라티 테라퓨틱스, 인크. | Lsd1 억제제 |
| AU2017233898B2 (en) | 2016-03-15 | 2022-12-15 | Oryzon Genomics, S.A. | Combinations of LSD1 inhibitors for use in the treatment of solid tumors |
| ES3042059T3 (en) | 2016-03-16 | 2025-11-18 | Oryzon Genomics Sa | Methods to determine kdm1a target engagement and chemoprobes useful therefor |
| HUE063848T2 (hu) * | 2016-10-26 | 2024-02-28 | Constellation Pharmaceuticals Inc | LSD1 gátlók és gyógyászati alkalmazásaik |
| EP3535420A1 (en) | 2016-11-03 | 2019-09-11 | Oryzon Genomics, S.A. | Biomarkers for determining responsiveness to lsd1 inhibitors |
| AU2018209164B2 (en) | 2017-01-17 | 2021-11-04 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| CN108530302A (zh) * | 2017-03-06 | 2018-09-14 | 华东师范大学 | 2`,3`-二氢螺[环丙烷-1,1`-茚]-2-胺衍生物及其制备方法和应用 |
| US10266542B2 (en) | 2017-03-15 | 2019-04-23 | Mirati Therapeutics, Inc. | EZH2 inhibitors |
| MY204406A (en) | 2017-08-03 | 2024-08-27 | Oryzon Genomics Sa | Methods of treating behavior alterations |
| FI4043466T3 (fi) | 2018-01-31 | 2024-10-30 | Mirati Therapeutics Inc | Prc2:n estäjiä |
| WO2020152280A1 (en) * | 2019-01-24 | 2020-07-30 | Fundación Pública Andaluza Progreso Y Salud | Lsd1 inhibitors for use in the treatment of type 2 diabetes |
| WO2020157069A1 (en) * | 2019-01-28 | 2020-08-06 | NodThera Limited | Amino heterocyclic compounds and uses thereof |
| BR112021016064A2 (pt) | 2019-03-20 | 2021-10-05 | Oryzon Genomics, S.A. | Métodos de tratamento do transtorno de personalidade borderline |
| CN120837494A (zh) | 2019-03-20 | 2025-10-28 | 奥莱松基因组股份有限公司 | 使用kdm1a抑制剂如化合物伐菲德司他治疗注意缺陷多动症的方法 |
| JP7624404B2 (ja) | 2019-04-22 | 2025-01-30 | ミラティ セラピューティクス，インク． | Ｐｒｃ２阻害剤としてのナフチリジン誘導体 |
| WO2020247475A1 (en) | 2019-06-05 | 2020-12-10 | Mirati Therapeutics, Inc. | Imidazo[1,2-c]pyrimidine derivatives as prc2 inhibitors for treating cancer |
| CN110256429B (zh) * | 2019-06-17 | 2021-06-22 | 广东药科大学 | 一种具有螺环结构的氨基嘧啶类化合物及其制备方法和应用 |
| JP2022546908A (ja) | 2019-07-05 | 2022-11-10 | オリゾン・ゲノミクス・ソシエダッド・アノニマ | Ｋｄｍ１ａ阻害剤を使用した小細胞肺がんの個別化された処置のためのバイオマーカーおよび方法 |
| CA3231846A1 (en) | 2021-04-08 | 2022-10-13 | Tamara Maes | Combinations of lsd1 inhibitors for treating myeloid cancers |
| EP4522136A1 (en) | 2022-05-09 | 2025-03-19 | Oryzon Genomics, S.A. | Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors |
| CN119497613A (zh) | 2022-05-09 | 2025-02-21 | 奥莱松基因组股份有限公司 | 使用lsd1抑制剂治疗nf1-突变肿瘤的方法 |
| AU2023385514A1 (en) | 2022-11-24 | 2025-07-10 | Oryzon Genomics, S.A. | Combinations of lsd1 inhibitors and menin inhibitors for treating cancer |
| WO2025085311A1 (en) * | 2023-10-16 | 2025-04-24 | Board Of Regents, The University Of Texas System | Methods and compositions for the treatment of kmt2d-deficient cancers |
| CN117510444B (zh) * | 2024-01-06 | 2024-03-08 | 成都瑞尔医药科技有限公司 | 一种呋塞米的精制工艺 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
| DE69025946T2 (de) | 1989-09-08 | 1996-10-17 | Univ Duke | Modifikationen der struktur des egf-rezeptor-gens in menschlichen glioma |
| AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
| GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
| ATE207366T1 (de) | 1993-12-24 | 2001-11-15 | Merck Patent Gmbh | Immunokonjugate |
| IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| US5654307A (en) | 1994-01-25 | 1997-08-05 | Warner-Lambert Company | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
| IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| ATE176910T1 (de) | 1994-07-21 | 1999-03-15 | Akzo Nobel Nv | Zyklische keton peroxyde zubereitungen |
| US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
| EP0817775B1 (en) | 1995-03-30 | 2001-09-12 | Pfizer Inc. | Quinazoline derivatives |
| GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| JPH11507535A (ja) | 1995-06-07 | 1999-07-06 | イムクローン システムズ インコーポレイテッド | 腫瘍の成長を抑制する抗体および抗体フラグメント類 |
| ATE212993T1 (de) | 1995-07-06 | 2002-02-15 | Novartis Erfind Verwalt Gmbh | Pyrolopyrimidine und verfahren zu ihrer herstellung |
| US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| EP0892789B2 (en) | 1996-04-12 | 2009-11-18 | Warner-Lambert Company LLC | Irreversible inhibitors of tyrosine kinases |
| AR007857A1 (es) | 1996-07-13 | 1999-11-24 | Glaxo Group Ltd | Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen. |
| ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
| UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| AU7165698A (en) | 1997-05-06 | 1998-11-27 | American Cyanamid Company | Use of quinazoline compounds for the treatment of polycystic kidney disease |
| ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| ZA986729B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
| TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
| CN1278176A (zh) | 1997-11-06 | 2000-12-27 | 美国氰胺公司 | 喹唑啉衍生物作为用于治疗结肠息肉的酪氨酸激酶抑制剂的应用 |
| EA003786B1 (ru) | 1998-11-19 | 2003-10-30 | Варнер Ламберт Компани | N-[4-(3-хлор-4-фторфениламино)-7-(3-морфолин-4-илпропокси)хиназолин-6-ил]акриламид - необратимый ингибитор тирозинкиназ |
| US7915295B2 (en) * | 2004-01-08 | 2011-03-29 | Medivir Ab | Non-nucleotide reverse transcriptase inhibitors |
| JPWO2010143582A1 (ja) * | 2009-06-11 | 2012-11-22 | 公立大学法人名古屋市立大学 | フェニルシクロプロピルアミン誘導体及びｌｓｄ１阻害剤 |
| EA022459B1 (ru) * | 2010-04-20 | 2016-01-29 | Университа' Дельи Студи Ди Рома "Ла Сапиенца" | Производные транилципромина в качестве ингибиторов гистон деметилаз lsd1 и/или lsd2 |
| LT2598482T (lt) * | 2010-07-29 | 2018-07-10 | Oryzon Genomics, S.A. | Demetilazės lsd1 inhibitoriai arilciklopropilamino pagrindu ir jų medicininis panaudojimas |
| CN103857393B (zh) * | 2011-03-25 | 2016-08-17 | 葛兰素史密斯克莱知识产权（第2号）有限公司 | 环丙基胺作为lsd1抑制剂 |
| UA114406C2 (uk) * | 2011-08-09 | 2017-06-12 | Такеда Фармасьютікал Компані Лімітед | Похідні циклопропанаміну як інгібітори lsd1 |
| EP3736265A1 (en) * | 2011-10-20 | 2020-11-11 | Oryzon Genomics, S.A. | (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors |
| CN106045862B (zh) * | 2015-04-10 | 2019-04-23 | 上海迪诺医药科技有限公司 | 环丙胺类螺(杂)环化合物、其药物组合物及应用 |
| WO2017109061A1 (en) * | 2015-12-23 | 2017-06-29 | Ieo - Istituto Europeo Di Oncologia S.R.L. | Spirocyclopropylamine derivatives useful as inhibitors of histone demethylases kdm1a |
-
2016
- 2016-01-28 EP EP16704983.2A patent/EP3250552B1/en active Active
- 2016-01-28 WO PCT/US2016/015440 patent/WO2016123387A1/en not_active Ceased
- 2016-01-28 JP JP2017539594A patent/JP6636031B2/ja not_active Expired - Fee Related
- 2016-01-28 CN CN201680019097.8A patent/CN107438593B/zh active Active
-
2017
- 2017-07-24 US US15/658,219 patent/US10301253B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018505169A5 (enExample) | ||
| JP2017530984A5 (enExample) | ||
| JP6905075B2 (ja) | 腫瘍の治療または予防のための併用療法 | |
| CO2023007504A2 (es) | Derivados de carboxamida tricíclica como inhibidores de prmt5 | |
| CL2023001738A1 (es) | Inhibidores de prmt5 | |
| RU2316326C2 (ru) | Способ и композиция для лечения ракового заболевания, тозилат и фармацевтически приемлемые соли n-(4-хлор-3-(трифторметил)фенил)-n'-(4-(2-(n-метилкарбамоил)-4-пиридилокси)фенил)мочевины | |
| JP2018510851A5 (enExample) | ||
| JP6456383B2 (ja) | イソチオシアネート系化合物と抗癌薬の併用 | |
| RU2018138828A (ru) | Уменьшение массы опухоли путем введения ccr1 антагонистов в комбинации с pd-1 ингибиторами или pd-l1 ингибиторами | |
| JP2014511383A5 (enExample) | ||
| RU2014111069A (ru) | Лекарственные формы ингибитора гистондиацетилазы в комбинации с бендамутином и их применение | |
| RU2014141362A (ru) | Комбинированная терапия пролиферативных нарушений | |
| RU2014102362A (ru) | Антитромботические соединения | |
| EP3053578B1 (en) | Combination cancer therapy using azabicyclo compound | |
| RU2014135436A (ru) | Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака | |
| RU2013127655A (ru) | Фармацевтическая комбинация паклитаксела и ингибитора cdk | |
| EA201500050A1 (ru) | Бифтордиоксалан-амино-бензимидазольные ингибиторы киназы для лечения рака, аутоиммунного воспаления и нарушений цнс | |
| JP2011140521A (ja) | タキサンにより惹起される神経毒性を予防又は軽減するための薬剤 | |
| RU2019141734A (ru) | Терапевтические соединения и композиции и способы их применения | |
| CA3116731A1 (en) | Combinations for immune-modulation in cancer treatment | |
| JP5514123B2 (ja) | 卵巣癌を治療するための、パクリタキセルを含む配合剤 | |
| CN102438608A (zh) | 包含ave8062和索拉非尼的抗肿瘤组合 | |
| ATE401080T1 (de) | (3-((chinazolin-4-yl)amino)-1h-pyrazol-1- yl)acetamid derivate und verwandte verbindungen als aurora kinase inhibitoren zur behandlung von proliferativen erkrankungen wie krebs | |
| RU2018107930A (ru) | Агонисты tlr4, их композиции и применение для лечения рака | |
| JP2019513812A5 (enExample) |